Innovating Evaluation and Treatment of Intrapartum Fevers: Where Do We Go from Here?

被引:0
作者
Wilkie, Gianna L. [1 ,2 ,3 ]
James, Kaitlyn [2 ]
Ona, Samsiya [1 ,2 ]
Easter, Sarah Rae [1 ]
Chou, Joseph [4 ]
Roberts, Drucilla [5 ]
Sahin, Zehra Ordulu [5 ]
Tuomala, Ruth [1 ]
Diouf, Khady [1 ]
Riley, Laura [2 ,6 ]
Prabhu, Malavika [2 ,6 ]
机构
[1] Harvard Med Sch, Dept Obstet & Gynecol, Brigham & Womens Hosp, Boston, MA USA
[2] Harvard Med Sch, Dept Obstet & Gynecol, Massachusetts Gen Hosp, Boston, MA USA
[3] Univ Massachusetts, Dept Obstet & Gynecol, Univ Massachusetts Med Sch, Mem Med Ctr, Worcester, MA USA
[4] Harvard Med Sch, Dept Pediat, Massachusetts Gen Hosp, Boston, MA USA
[5] Harvard Med Sch, Dept Pathol, Massachusetts Gen Hosp, Boston, MA USA
[6] Weill Cornell Med, Dept Obstet & Gynecol, New York, NY USA
关键词
intrapartum fever; early onset sepsis; intraamniotic infection; POLYMERASE-CHAIN-REACTION; EARLY-ONSET SEPSIS; INFLAMMATORY RESPONSE; ANTIBIOTIC USE; MANAGEMENT; RISK; CHORIOAMNIONITIS; INTERLEUKIN-6; BACTEREMIA; NEWBORNS;
D O I
10.1055/s-0041-1727279
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
As intrapartum fevers are not always infectious in origin, determining whether antibiotics are indicated is challenging. We previously sought to create a point-of-care calculator using clinical data available at the time of an intrapartum fever to identify the subset of women who require antibiotic treatment to avoid maternal and neonatal morbidity. Despite the use of a comprehensive dataset from our institutions, we were unable to propose a valid and highly predictive model. In this commentary, we discuss why our model failed, as well as future research directions to identify and treat true intraamniotic infection. Developing a risk-stratification model is paramount to minimizing maternal and neonatal exposure to unnecessary antibiotics while allowing for early identification of women and babies at risk for infectious morbidity.
引用
收藏
页码:250 / 254
页数:5
相关论文
共 50 条
  • [41] Stroke prevention in heart failure and sinus rhythm: where do we go from here?
    Vaduganathan, Muthiah
    Patel, Ravi B.
    Yancy, Clyde W.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (10) : 1267 - 1269
  • [42] Late-life depression in primary care: Where do we go from here?
    Banazak, Deborah A.
    Wills, Celia
    Collins, Clare
    JOURNAL OF OSTEOPATHIC MEDICINE, 2023, 98 (09): : 489 - 497
  • [43] Basel III: where should we go from here?
    Quang Thi Thieu Nguyen
    JOURNAL OF FINANCIAL ECONOMIC POLICY, 2019, 11 (04) : 457 - 469
  • [44] Thirty-five Years of Acute Pain Services: Where Do We Go From Here?
    Stamer, Ulrike M.
    Liguori, Gregory A.
    Rawal, Narinder
    ANESTHESIA AND ANALGESIA, 2020, 131 (02) : 650 - 656
  • [45] Managing low back pain presenting to primary care: Where do we go from here?
    Macfarlane, Gary J.
    Jones, Gareth T.
    Hannaford, Philip C.
    PAIN, 2006, 122 (03) : 219 - 222
  • [46] Where Do We Go From Here? Progressing Sustainability Implementation Efforts Across Supply Chains
    Brockhaus, Sebastian
    Kersten, Wolfgang
    Knemeyer, A. Michael
    JOURNAL OF BUSINESS LOGISTICS, 2013, 34 (02) : 167 - 182
  • [47] Analysis of process model reuse: Where are we now, where should we go from here?
    Koschmider, Agnes
    Fellmann, Michael
    Schoknecht, Andreas
    Oberweis, Andreas
    DECISION SUPPORT SYSTEMS, 2014, 66 : 9 - 19
  • [48] Health Literacy, Vulnerable Patients, and Health Information Technology Use: Where Do We Go from Here?
    Lyles, Courtney R.
    Sarkar, Urmimala
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2015, 30 (03) : 271 - 272
  • [49] The (UK) Freedom of Information Act's disclosure process is broken: where do we go from here?
    Pearce, Henry
    INFORMATION & COMMUNICATIONS TECHNOLOGY LAW, 2020, 29 (03) : 354 - 390
  • [50] Empirically Based Treatments for Family Caregiver Distress: What Works and Where Do We Go from Here?
    Coon, David W.
    Evans, Bronwynne
    GERIATRIC NURSING, 2009, 30 (06) : 426 - 436